Video

Dr. Aggarwal on Androgen Deprivation Therapy for Prostate Cancer

Rahul Aggarwal, MD, assistant professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Comprehensive Cancer Center, discusses androgen deprivation therapy for patients with prostate cancer.

Rahul Aggarwal, MD, assistant professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Comprehensive Cancer Center, discusses androgen deprivation therapy for patients with prostate cancer.

According to Aggarwal, we are moving away from a one-size-fits-all approach for androgen deprivation therapy to one that is adaptive for a patient’s specific disease state. Physicians are focused on the recent data in regards to abiraterone (Zytiga) and AR-targeted therapies.

Related Videos
Werutsky
Dr Sekkeres on the Association Between Smoking and Disease Progression in MDS
Lori Muffly, MD
Pooja Phull, MD
Eric Winer, MD
Jennifer Effie Amengual, MD
Michael R. Bishop, MD
Marwan G. Fakih, MD, discusses the FDA approval of sotorasib with panitumumab for the treatment of adult patients with KRAS G12C–mutated metastatic colorectal cancer.
C. Ola Landgren, MD, PhD